Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly
August 07, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly,...
Fulcrum Therapeutics Appoints Chief Financial Officer
August 03, 2023 06:55 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Jasper Therapeutics Strengthens Management Team with Key Appointments
August 02, 2023 08:00 ET
|
Jasper Therapeutics
Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE...
Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
July 06, 2023 16:05 ET
|
Nasdaq, Inc.
NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the ordinary shares of Puhui Wealth Investment Management Co., Ltd. Puhui Wealth Investment...
Tumor Infiltrating Lymphocytes Global Market Report 2023
May 30, 2023 12:33 ET
|
ReportLinker
New York, May 30, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tumor Infiltrating Lymphocytes Global Market Report 2023" -...
Tumor Infiltrating Lymphocytes Global Market Report 2023: Sector to Reach $15.56 Billion by 2027 at a 13.7% CAGR
May 23, 2023 04:53 ET
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Tumor Infiltrating Lymphocytes Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global tumor infiltrating...
Global Engineered T Cells Market Report 2023: Increasing Demand for Innovative Biopharmaceutical Therapies Boosts Sector
May 19, 2023 08:48 ET
|
Research and Markets
Dublin, May 19, 2023 (GLOBE NEWSWIRE) -- The "Global Engineered T Cells Market by Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), Application (Breast Cancer,...
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
March 14, 2023 16:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and...
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater...
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 18:43 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...